Literature DB >> 21789069

Minimally-invasive correction of ureteropelvic junction obstruction: do retrograde endo-incision techniques still have a role in the era of laparoscopic pyeloplasty?

Shawky A Elabd1, Abdelhamid M Elbahnasy, Yaser A Farahat, Mohamed G Soliman, Mohamed R Taha, Mohmed A Elgarabawy, Robert Figenshau.   

Abstract

BACKGROUND: This study was designed to review the long-term results and complications of the two techniques of retrograde endopyelotomy; ureteroscopic holmium laser endopyelotomy versus Acucise endopyelotomy. The results were then compared with the laparoscopic pyeloplasty results from a recent publication. PATIENTS AND METHODS: : The study was conducted retrospectively from January 2004 to July 2007. Seventy-two patients with ureteropelvic junction obstruction (UPJO) underwent retrograde endopyelotomy using either ureteroscopic laser endoincision (42 patients) or fluoroscopic guided hot-wire balloon (Acucise) endoincision (30 patients). Preoperative radiological assessment included intravenous pyelogram (IVP), helical computerized tomography and diuretic renography. The follow-up period ranged from 12 to 42 months. Subjective success was guided by the change in the preoperative flank pain while objective success on radiological evaluation was documented by either nonobstructed curve of diuretic renogram and/or T1/2 less than 10 min.
RESULTS: The mean patient age was 42.6 ± 7.5 years for the laser group and 39.2 ± 15.1 years for the Acucise group (p = 0.24). The operative time was 66.8 ± 22.2 min in the laser group and 59.8 ± 20.3 min in the Acucise group (p = 0.84). By objective standards (renal scan), a total of 56 (77.8%) cases were successful (nonobstructed curve). This number included 34 cases in the laser group (80.9%) and 22 cases in the Acucise group (73.3%) (p = 0.2). Overall 16 failure cases were evident clinically within 1 year of the procedure (eight cases in each group). Most of the failure cases (13/16) presented with clinical obstructive symptoms during the early follow-up period (within 3 months postoperatively) and were then confirmed radiologically (six cases in the laser group and seven cases in the Acucise group) while only three patients had failures at 6, 9 and 11 months postoperatively. There was no statistically significant difference as regards intra-operative complications between the two groups (p = 0.4). Intra-operative bleeding was seen in three cases in the Acucise group while postoperatively it was reported in one case.
CONCLUSION: The retrograde endopyelotomy approach is safe and effective for the treatment of patients with UPJO. Both ureteroscopic laser and the hot-wire balloon (Acucise) techniques have an important role in the management of UPJO, especially in secondary cases, and they provide comparable long-term objective and subjective outcomes. Laparoscopic pyeloplasty provides far better results but with higher costs, and requires well-equipped centers and involves a long learning curve.

Entities:  

Keywords:  endoscopy; laproscopy; retrograde; ureteropelvic junction obstruction

Year:  2009        PMID: 21789069      PMCID: PMC3126076          DOI: 10.1177/1756287210362070

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  23 in total

Review 1.  Ureteropelvic junction obstruction. Retrograde endopyelotomy.

Authors:  S Y Nakada; M Johnson
Journal:  Urol Clin North Am       Date:  2000-11       Impact factor: 2.241

2.  Retrograde ureteroscopic endopyelotomy using the holmium:YAG laser.

Authors:  J L Giddens; M Grasso
Journal:  J Urol       Date:  2000-11       Impact factor: 7.450

3.  Prospective, randomized comparison of ureteroscopic endopyelotomy using holmium:YAG laser and balloon catheter.

Authors:  Ahmed R el-Nahas; Ahmed M Shoma; Ibrahim Eraky; Mahmoud R el-Kenawy; Hamdy A el-Kappany
Journal:  J Urol       Date:  2006-02       Impact factor: 7.450

4.  Outpatient holmium laser lithotripsy using semirigid ureteroscope. Is the treatment outcome affected by stone load?

Authors:  M C Cheung; F Lee; S K Yip; P C Tam
Journal:  Eur Urol       Date:  2001-06       Impact factor: 20.096

5.  [Complications of "Acucise" balloon endopyelotomy].

Authors:  Jochen Walz; Catherine Lecamus; Eric Lechevallier; David Barriol; Denis Bretheau; Paul Albert; Michel Hermanowicz; Christian Coulange
Journal:  Prog Urol       Date:  2003-02       Impact factor: 0.915

6.  Ureteroscopic endopyelotomy with the Holmium:YAG laser. mid-term results.

Authors:  C S Biyani; P A Cornford; C S Powell
Journal:  Eur Urol       Date:  2000-08       Impact factor: 20.096

Review 7.  Complications of retrograde balloon cautery endopyelotomy.

Authors:  B F Schwartz; M L Stoller
Journal:  J Urol       Date:  1999-11       Impact factor: 7.450

8.  Complications of acucise endopyelotomy.

Authors:  F J Kim; S D Herrell; A E Jahoda; D M Albala
Journal:  J Endourol       Date:  1998-10       Impact factor: 2.942

9.  Ureteroscopic laser endopyelotomy: a single-center experience.

Authors:  Surena F Matin; Agnes Yost; Stevan B Streem
Journal:  J Endourol       Date:  2003-08       Impact factor: 2.942

Review 10.  Ureteroscopic treatment of ureteropelvic junction obstruction.

Authors:  E R Tawfiek; J B Liu; D H Bagley
Journal:  J Urol       Date:  1998-11       Impact factor: 7.450

View more
  3 in total

Review 1.  Laser endoureterotomy and endopyelotomy: an update.

Authors:  Esteban Emiliani; Alberto Breda
Journal:  World J Urol       Date:  2014-09-23       Impact factor: 4.226

Review 2.  Minimally Invasive Techniques for the Management of Adult UPJ Obstruction.

Authors:  Marshall C Strother; Phillip Mucksavage
Journal:  Curr Urol Rep       Date:  2016-05       Impact factor: 3.092

3.  Simultaneous laparoscopic management of ureteropelvic junction obstruction and renal lithiasis: the combined experience of two academic centers and review of the literature.

Authors:  Konstantinos G Stravodimos; Stilianos Giannakopoulos; Stavros I Tyritzis; Aristeides Alevizopoulos; Stefanos Papadoukakis; Stavros Touloupidis; Constantinos A Constantinides
Journal:  Res Rep Urol       Date:  2014-05-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.